DR Magdalene Montgomery

DR Magdalene Montgomery


  • Fatty liver disease (Non-alcoholic fatty liver disease)
  • Metabolic Cross-talk; Endocrine Signalling (Understanding endocrine crosstalk in pathophysiological conditions)
  • Type 2 Diabetes (Mouse models of insulin resistance)



  • Dr Magda Montgomery is a NHMRC CDF1 Fellow and a Group Leader in the Department of Physiology at the University of Melbourne. Dr Montgomery received her PhD at the University of Wollongong in 2011, and her postdoctoral training in the area of metabolic disease and tissue cross-talk at the Garvan Institute in Sydney (2011 – 2013), at the University of New South Wales (2013 – 2016), and at Monash University (2016 – 2018). Dr Montgomery recently moved to the University of Melbourne, where she is currently investigating links between perturbations in liver homeostasis and the development of type 2 diabetes, with a special focus on liver-secreted proteins and their effects on glycaemic control.   


Member of

  • Editorial Board for Biochemical Pharmacology. Editorial Board Member 2018 -
  • Australian Diabetes Society (ADS). Member of the Australian Diabetes Society 2012 -
  • European Association for the Study of Diabetes (EASD). Member of the European Association for the Study of Diabetes 2012 -
  • American Physiological Society (APS). Member of the American Physiological Society 2008 - 2012
  • Australian and New Zealand Society for Comparative Physiology and Biochemistry (ANZSCPB). Member of the Australian and New Zealand Society for Comparative Physiology and Biochemistry 2008 - 2012


Selected publications


Additional Grant Information

  • 2019 Chief Investigator (CIB) on NHMRC project grant – Commencing 2019, duration 3 years, $772,000
    Application title: Discovery and validation of biomarkers for nonalcoholic steatohepatitis and liver fibrosis

    2018 NHMRC Career Development (CDF1) fellowship (2018 – 2022; $431,000)
    Application title: Understanding Mediators of Metabolic Disease

    2017 Chief Investigator (CIA) on FMNHS Advancing Women in Research Grants, Monash University, $10,000
    Application title: Biomarker discovery for non-alcoholic steatohepatitis

    2017 Chief Investigator (CIA) on Faculty of Medicine, Nursing and Health Sciences (FMNHS) Strategic Grants Scheme (SGS), Monash University, $45,000
    Application title: Secretome Profiling in mouse models of nonalcoholic steatohepatitis (NASH)

    2016 Chief Investigator (CIB) on UNSW GoldStar Award, University of New South Wales, $40,000
    Application title: Understanding sphingolipid mediators of insulin resistance

    2015 Chief Investigator (CIB) on successful Diabetes Australia Research Trust (DART) grant, $60,000
    Application title: Defining sphingolipid mediators of hepatic insulin resistance

    2013 NHMRC Peter Doherty Early Career Fellowship – Commencing Jan2014, duration 4 years, $305,000
    Application Title: The beneficial effects of medium-chain fatty acids in obesity and insulin resistance

    2013 Chief Investigator (CID) on NHMRC project grant – Commencing Jan2014, duration 3 years, $513,000
    Application Title: Investigation of the mechanism by which medium chain fatty acids prevent the development of obesity and insulin resistance - what role for GPR84?   


Education and training

  • PhD, University of Wollongong 2011
  • BSc (Hons), Philipps-Universitat Marburg 2008
  • Bsc, Universitaet Bielefeld 2005

Awards and honors

  • NHMRC Fellowship, 2018
  • International Travel Award from the European Association for the Study of Diabetes (EASD), European Association for the Study of Diabetes (EASD), 2016
  • Early Career Research Travel Award, School of Medical Sciences, University of New South Wales, 2015
  • Researcher of the Year, Faculty of Medicine, University of New South Wales, 2014
  • Award for Best PhD Seminar, University of Wollongong, 2010
  • International Travel Grant, Research Student Centre, University of Wollongong, 2010
  • International Travel Grant, Faculty of Science, University of Wollongong, 2010
  • Award for Best Seminar, 26th Annual Meeting of the Australian and New Zealand Society for Comparative Physiology and Biochemistry (ANZSCPB),, 2009
  • University of Wollongong Fee Waiver Scholarship, University of Wollongong, 2008
  • University of Wollongong Postgraduate Award, University of Wollongong, 2008



Available for supervision

  • Y

Supervision Statement

  • 2019: B.Sci(Hon) Honours Supervisor: Camille Devereux
    Thesis Title: Exercise-induced hepatokines

    2019: B.Sci(Hon) Honours Supervisor: Amanuiel Taddese
    Thesis Title: Hexosaminidase A (HEXA) – A new target for glycaemic control

    2018 – Current: PhD supervisor: William De Nardo
    Thesis Title: Secretome profiling in non-alcoholic steatohepatitis (NASH)

    2018 – Current: PhD supervisor: Hamzeh Karimkhanloo
    Thesis Title: The inter-connect between liver disease and glycaemic control

    2016 – Current: PhD supervisor: Stacey Keenan
    Thesis Title: Investigating the effects of the lipid droplet protein Perilipin 5 on liver metabolism and glycaemic control.

    2016: B.Sci(Hon) Honours Supervisor: William Cain
    Thesis Title: The role of SMOC1 in adipocyte glucose and fatty acid metabolism.

    2016: B.Sci(Hon) Honours Supervisor: Deeksha Rao
    Thesis title: The effect of SMOC1 on glycaemic control.

    2014 – 2017: PhD supervisor: Nicholas Bentley (submitted Dec 2017 – PhD March 2018)
    Thesis Title: Elevating mitochondrial NAD+ levels to ameliorate the process of ageing and metabolic disease

    2014: Primary Supervisor (3rd year Research Internship): Hui Xin Saw, Project: Evaluating the effect of novel ceramide synthase inhibitors on hepatic sphingolipid composition and insulin signaling

    2012: B.Sci.(Hon) Co-Supervisor: Menghan Liu
    Thesis title: The mechanisms by which fish oil protects against lipid-induced adiposity and insulin resistance

    2012: Primary Masters Supervisor: Luke Chisholm (overseas placement student from the University of Bath, England, Jan-Oct 2012)
    Project: The role of medium-chain fatty acids and GPR84 in insulin resistance